Inference of Type-Specific HPV Transmissibility, Progression and Clearance Rates: A Mathematical Modelling Approach

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Johnson, Helen C ^a   Elfström, K Miriam ^b   Edmunds, W John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNITY; MALE; MATHEMATICAL MODEL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHYLOGENY; PREVALENCE; SCREENING; SEXUAL BEHAVIOR; SURVIVAL; SWEDEN; VIRAL CLEARANCE; VIRUS TRANSMISSION; WART VIRUS;

EID: 84869842317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049614     Document Type: Article

References (32)

1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology 189: 12-19.
2. Franco EL, Villa LL, Sobrinho JoP, Prado JM, Rousseau M-C, et al. (1999) Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High-Risk Area for Cervical Cancer. Journal of Infectious Diseases 180: 1415-1423.
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV, (2002) The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 55: 244-265.
4. Bulkmans NWJ, Berkhof J, Bulk S, Bleeker MCG, van Kemenade FJ, et al. (2007) High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 96: 1419-1424.
5. Jit M, Gay N, Soldan K, Hong Choi Y, Edmunds WJ, (2010) Estimating Progression Rates for Human Papillomavirus Infection From Epidemiological Data. Medical Decision Making 30: 84-98.
6. Bulkmans NWJ, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, et al. (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. The Lancet 370: 1764-1772.
7. Castle PE, Solomon D, Schiffman M, Wheeler CM, for the AG, (2005) Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. Journal of the National Cancer Institute 97: 1066-1071.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, et al. (2005) The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice. Journal of the National Cancer Institute 97: 1072-1079.
9. Berkhof J, Bulkmans NWJ, Bleeker MCG, Bulk S, Snijders PJF, et al. (2006) Human Papillomavirus Type "Specific 18-Month Risk of High-Grade Cervical Intraepithelial Neoplasia in Women with a Normal or Borderline/Mildly Dyskaryotic Smear. Cancer Epidemiology Biomarkers & Prevention. 15: 1268-1273.
10. Sanders GD, Taira AV, (2003) Cost-effectiveness of a potential vaccine for human papillomavirus. Emerging infectious diseases 9: 37-48.
11. Hughes JP, Garnett GP, Koutsky L, (2002) The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine. Epidemiology 13: 631-639.
12. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, et al. (2003) A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. International Journal of Cancer 106: 896-904.
13. Barnabas RV, Laukkanen Pi, Koskela P, Kontula O, Lehtinen M, et al. (2006) Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses. PLoS Med 3: e138.
14. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB, (2000) Mathematical Model for the Natural History of Human Papillomavirus Infection and Cervical Carcinogenesis. American Journal of Epidemiology 151: 1158-1171.
15. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD, (1998) Natural History of Cervicovaginal Papillomavirus Infection in Young Women. New England Journal of Medicine 338: 423-428.
16. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, et al. (2008) Type-Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination. Journal of Infectious Diseases 197: 1436-1447.
17. Remmink AJ, Walboomers JMM, Helmerhorst TJM, Voorhorst FJ, Rozendaal L, et al. (1995) The presence of persistent high-risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. International Journal of Cancer 61: 306-311.
18. Kulasingam S, Benard S, Barnabas R, Largeron N, Myers E, (2008) Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 6: 1-11.
19. Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, et al. (2006) Estimating the long-term impact of a prophylactic human papillomavirus 16//18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96: 143-150.
20. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, et al. (2007) Multiparameter Calibration of a Natural History Model of Cervical Cancer. American Journal of Epidemiology 166: 137-150.
21. Van de Velde N, Brisson M, Boily M-C, (2007) Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty. American Journal of Epidemiology 165: 762-775.
22. Bogaards JA, Xiridou M, Coupé VMH, Meijer CJLM, Wallinga J, et al. (2010) Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology 171: 817-825.
23. Lewin B, Fugl-Meyer K, Helmius GL, Ann Månsson S-A (2000) Sex in Sweden- On the Swedish Sexual Life: The National Institute of Public Health.
24. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, et al. (2008) Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions. Vaccine 26Supplement 10: K17-K28.
25. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, et al. (2007) Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. New England Journal of Medicine 357: 1589-1597.
26. Forslund O, Antonsson A, Edlund K, van den Brule AJC, Hansson B-G, et al. (2002) Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish Women. Journal of Medical Virology 66: 535-541.
27. Elfgren K, Rylander E, Rådberg T, Strander B, Strand A, et al. (2005) Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. American Journal of Obstetrics and Gynecology 193: 650-657.
28. Bogaards JA, Xiridou M, Coupé VMH, Meijer CJLM, Wallinga J, et al. (2010) Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus. American Journal of Epidemiology 171: 817-825.
29. Hastings WK, (1970) Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57: 97-109.
30. Baussano I, Ronco G, Segnan N, French K, Vineis P, et al. (2010) HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. Epidemics 2: 21-28.
31. Kim JJ, (2006) Mathematical Model of HPV Provides Insight into Impacts of Risk Factors and Vaccine. PLoS Med 3: e164.
32. Baussano I, Garnett G, Segnan N, Ronco G, Vineis P, (2011) Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 29: 1270-1277.